Search clinical trials for: Perampanel Tablet

Total 7393 results

Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Tasly Pharmaceutical Group Co., Ltd

Completed

Study of Jitongning Tablet to Treat Spondyloarthritis

Spondyloarthritis

China
University of Arizona
Eisai Inc.

Completed

Fycompa Titration Intervals and Effects on Retention Rate

Epilepsy

United States
Stony Brook University
Eisai Inc.

Terminated

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Eisai Inc.

Completed

Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)

Neuralgia

United States, Canada
Kimford Jay Meador
Eisai Inc.

Recruiting

Perampanel Titration and Cognitive Effects

Epilepsy

United States
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, Chile, Brazil, Canada, Mexico, Argentina
Eisai Inc.

Completed

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, France, Germany, Italy, United Kingdom, Belgium, Israel, South Africa, Finland, Russian Federation, Austria, Netherlands, Sweden, India
Weill Medical College of Cornell University
Eisai Inc.

Completed

Effects of Perampanel on Neurophysiology Test Perimeters

Healthy

United States
National Taiwan University Hospital

Completed

The Efficacy of Fycompa (Perampanel) in Children With Epilepsy

Neurologic Disorder

Taiwan
University Health Network, Toronto
Dystonia Study Group

Completed

Safety and Tolerability of Perampanel in Cervical Dystonia (SAFE-PER-CD)

Cervical Dystonia

United States, Canada
Hospices Civils de Lyon

Completed

Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon) (PERLYON)

Refractory Epilepsy

France
Eisai Inc.

Completed

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

Epilepsy

Belgium, France, United States, Czech Republic, Estonia, Latvia, Spain, United Kingdom, Lithuania, Germany, Australia, Finland, Netherlands, Sweden
Eisai Inc.

Completed

Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

Healthy

United States
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
Eisai Inc.

Withdrawn

To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures

Epilepsy, Partial
Eisai Inc.

Completed

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

Epilepsy

Belgium, Israel, United Kingdom, Austria, Sweden, Czechia
Eisai Co., Ltd.

Completed

A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects

Healthy

Korea, Republic of
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects

Partial Onset Epilepsy

United Kingdom
Carilion Clinic

Recruiting

Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

Epilepsy | Seizures

United States
Eisai Inc.

Completed

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Canada, France, Italy, Korea, Republic of, Spain, United States, Belgium, Czechia, Hungary, Japan, Latvia, Poland
Eisai Inc.

Completed

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Epilepsy

Belgium, Germany, China, Hong Kong, United States, France, Romania, Mexico, South Africa, India, Portugal, Russian Federation, Italy, Canada, Australia, Taiwan, Austria, Malaysia, Hungary, Poland, Thailand, Sweden, Bulgaria, Serbia, Greece and more
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects

Healthy Subjects
Eisai Inc.

Completed

Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects

Healthy

United States
Yiling Pharmaceutical Inc.

Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease

China
Mayo Clinic

Completed

Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized Seizures

United States
Seoul National University Hospital

Completed

Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy

Electroencephalography

Korea, Republic of
Eisai Inc.

Completed

Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

Healthy Participants

United States
Eisai Inc.

Completed

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Neuralgia

United States
Eisai Inc.

Terminated

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease
Eisai Inc.

Completed

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Epilepsy

United States, Latvia
American University of Beirut Medical Center

Terminated

Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients

Amyotrophic Lateral Sclerosis

Lebanon
Chinese University of Hong Kong

Unknown

Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong

Generalized Epilepsy | Focal Epilepsy | Partial Seizures, Simple

Hong Kong
Eisai Korea Inc.

Completed

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Epilepsy

Korea, Republic of
Eisai Inc.

Completed

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

Epilepsy

United States, Poland, Belgium, India, Korea, Republic of, Thailand, Hungary, Latvia, Czechia, Australia, Spain
Eisai Inc.

Completed

Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Epilepsy

United States
Eisai Co., Ltd.

Completed

Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Healthy Participants

Japan
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

Healthy Subjects

China
VA Greater Los Angeles Healthcare System

Unknown

An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor

Essential Tremor

United States
The National Institutes of Pharmaceutical R&D Co...

Completed

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Idiopathic Pulmonary Fibrosis

United States
Eisai Inc.

Completed

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Seizure Disorder Generalized Tonic Clonic
Eisai Inc.

Completed

Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

United States, Canada
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Eisai Inc.

Terminated

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome (LGS)

Korea, Republic of, United States, Australia, Belgium, Japan, Czechia, India
Eisai Co., Ltd.

Completed

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Korea, Republic of, Japan, Australia, China, Malaysia, Taiwan, Thailand
Eisai Pharmaceuticals India Pvt. Ltd

Completed

A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

Epilepsy | Partial Onset Seizures

India
Eisai Limited

Completed

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Partial Seizures
Eisai Co., Ltd.

Completed

An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects

Epilepsy

Japan
Eisai Korea Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Epilepsy

Korea, Republic of

3

Subscribe